These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31407671)

  • 1. Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial.
    Yamamoto K; Ioroi T; Harada K; Nishiyama S; Nishigori C; Yano I
    JMIR Res Protoc; 2019 Aug; 8(8):e14636. PubMed ID: 31407671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
    Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
    Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
    Chu D; Lacouture ME; Weiner E; Wu S
    Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy.
    Naeem SS; Gupta P; Sahoo RK; Kumar VL; Velpandian T; Singh A; Batra A; Pramanik R; Rastogi S; Srivastava S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102073. PubMed ID: 38626661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
    Manchen E; Robert C; Porta C
    J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial.
    Tanigawa T; Nomura A; Kuroda M; Muto T; Hida E; Satake K
    JMIR Res Protoc; 2019 Jul; 8(7):e12701. PubMed ID: 31290402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
    Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
    BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
    Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial.
    Nomura A; Tateno H; Masaki K; Muto T; Suzuki S; Satake K; Hida E; Fukunaga K
    JMIR Res Protoc; 2019 Feb; 8(2):e12252. PubMed ID: 30741641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial.
    Kawai Y; Sankoda A; Waki K; Miyake K; Hayashi A; Mieno M; Wakui H; Tsurutani Y; Saito J; Hirawa N; Yamakawa T; Komiya S; Isogawa A; Satoh S; Minami T; Osada U; Iwamoto T; Takano T; Terauchi Y; Tamura K; Yamauchi T; Kadowaki T; Nangaku M; Kashihara N; Ohe K
    JMIR Res Protoc; 2021 Aug; 10(8):e31061. PubMed ID: 34402802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.
    Yeh CN; Chung WH; Su SC; Chen YY; Cheng CT; Lin YL; Chang WC; Chung-Yee Hui R; Chiang KC; Chen TW; Jan YY; Chen CW; Chen TJ; Yang CH; Hung SI
    J Invest Dermatol; 2014 Nov; 134(11):2768-2775. PubMed ID: 24802849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
    McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
    Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Remote Cardiac Rehabilitation in the Recovery Phase of Cardiovascular Diseases: Protocol for a Multicenter, Nonrandomized, Single-Arm, Interventional Trial.
    Itoh H; Amiya E; Narita K; Shimbo M; Taya M; Komuro I; Hasegawa T; Makita S; Kimura Y
    JMIR Res Protoc; 2021 Oct; 10(10):e30725. PubMed ID: 34407925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
    Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
    Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
    J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
    Pandy JGP; Franco PIG; Li RK
    Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.
    Hasan Alshammari A; Masuo Y; Fujita KI; Shimada K; Iida N; Wakayama T; Kato Y
    Biochem Pharmacol; 2022 Mar; 197():114914. PubMed ID: 35041812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internet-Based Individualized Cognitive Behavioral Therapy for Shift Work Sleep Disorder Empowered by Well-Being Prediction: Protocol for a Pilot Study.
    Ito-Masui A; Kawamoto E; Sakamoto R; Yu H; Sano A; Motomura E; Tanii H; Sakano S; Esumi R; Imai H; Shimaoka M
    JMIR Res Protoc; 2021 Mar; 10(3):e24799. PubMed ID: 33626497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs: Protocol for a prospective, randomized, controlled, double-blind, and monocentric clinical trial.
    Wang G; Jia L; Pei Y; Yu R; Gao Y; Deng C; Lou Y
    Medicine (Baltimore); 2020 Jan; 99(4):e18849. PubMed ID: 31977883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.